<div id="readability-page-1">NovoCure (NVCR) is scheduled to announce Q1 earnings results on Thursday, April 30th, before market open. The consensus EPS Estimate is -$0.51 (-64.5% Y/Y) and the consensus Revenue Estimate is $167.77M (+8.2% Y/Y). Over the last 2 years, NVCR has beaten EPS estimates 63% of the time and has beaten revenue estimates 63% of the time. Over the last 3...</div>

NVCR

SBIO

LABU

<p>NovoCure (NVCR) will announce its Q1 earnings on April 30th, with a consensus EPS estimate of -$0.51, reflecting a 64.5% year-over-year decline, and a revenue estimate of $167.77 million, indicating an 8.2% year-over-year increase. The company has a track record of beating EPS and revenue estimates 63% of the time over the past two years.</p>

Novocure

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

NovoCure Q1 2026 earnings preview